Shared manufacturing platform
All KNX programs use the same E. coli expression system and recombinant protein production process — manufacturing efficiencies scale across the entire pipeline.
Pipeline
One platform. Multiple pathogens. Vaccines and therapeutics.
The patented pAMP platform enables rapid deployment across disease indications — from precision prophylactic vaccines against high-consequence infectious diseases to multi-pathogen therapeutic candidates with no approved countermeasures.
| Program | Pathogen | Indication | Stage | Funding Pathway |
|---|---|---|---|---|
| KNX-001 | Andes Virus (ANDV) | Hantavirus Pulmonary Syndrome (HPS) | Preclinical | Prophylactic Vaccine |
| KNX-002 | Rift Valley Fever Virus (RVFV) | Rift Valley Fever (RVF) | Preclinical | Prophylactic Vaccine |
| KNX-003 | RVFV & Hantavirus | Multi-Pathogen Viral Therapeutic | Discovery | Standalone Therapeutic |
| KNX-004 | RVFV & Hantavirus | Preventive / Therapeutic Combination Vaccine | Concept | Under Discussion |
Swipe the table horizontally to see all columns.
4
Programs across vaccines and therapeutics
Zero
Approved vaccines or therapeutics for any KNX target
4
Active programs across high-consequence infectious diseases
One
Modular platform powering all programs
KNX-001 — Prophylactic Vaccine
Hantavirus Pulmonary Syndrome
HPS is a severe respiratory illness caused by New World hantaviruses, of which Andes virus (ANDV) is among the most consequential. There are no approved vaccines or therapeutics, and the reported case fatality rate is 35–40%.
The 2026 multi-country Andes hantavirus outbreak aboard the MV Hondius cruise ship, declared by WHO, further underscores the urgent and active public health threat posed by ANDV, an agent posing high risk due to its potential for dissemination, high mortality, and lack of approved countermeasures.
Kinexar's pAMP-based HPS vaccine candidate is designed to elicit broad neutralizing antibody and T-cell responses, combining multi-epitope coverage with a thermostable, non-replicating format suited to national stockpiling.
KNX-001
Program profile
- Platform
- Patented pAMP concatemeric peptide
- Pathogen
- Andes virus (ANDV)
- Indication
- Hantavirus Pulmonary Syndrome (HPS)
- Modality
- Prophylactic vaccine
- Stage
- Preclinical
- Immune objective
- Broad neutralizing antibody and T-cell responses
KNX-002 — Prophylactic Vaccine
Rift Valley Fever
Rift Valley Fever Virus (RVFV) is a Category A/B priority pathogen causing severe hemorrhagic fever in humans and catastrophic livestock losses. No licensed human vaccine exists. The 2025–2026 Senegal outbreak and WHO designation as a priority pathogen for pandemic preparedness underscore the urgency.
KNX-002 applies the patented pAMP platform to RVFV Gn/Gc glycoprotein epitopes, targeting the same neutralizing antibody response that confers protection in natural infection. A single platform approach enables parallel development alongside KNX-001 with shared manufacturing infrastructure.
KNX-002
Program profile
- Platform
- Patented pAMP concatemeric peptide
- Pathogen
- Rift Valley Fever Virus (RVFV)
- Indication
- Rift Valley Fever (RVF)
- Modality
- Prophylactic vaccine
- Stage
- Preclinical
- Immune objective
- Neutralizing antibodies targeting Gn/Gc glycoproteins
KNX-003 — Standalone Therapeutic
Multi-Pathogen Antiviral Therapeutic
KNX-003 is a pAMP-based antiviral therapeutic candidate targeting a conserved viral virulence factor shared across both RVFV and hantaviruses. The target plays a key role in immune evasion, and no approved therapeutic against it exists for either pathogen.
By leveraging the patented pAMP platform's concatemeric architecture, KNX-003 is designed to engage its target with multi-valent binding, restoring host immune competence. Because the target is conserved across both pathogen families, a single KNX-003 candidate addresses both RVFV and hantavirus — a cross-pathogen therapeutic with no equivalent in development.
KNX-003
Program profile
- Platform
- Patented pAMP concatemeric peptide
- Target
- Conserved viral virulence factor (RVFV & hantavirus)
- Indication
- Multi-pathogen viral therapeutic
- Modality
- Standalone therapeutic
- Stage
- Discovery
- Mechanism
- Multi-valent binding — restores host immune competence
KNX-004 — Under Discussion
Preventive / Therapeutic Combination Vaccine
KNX-004 is a concept-stage program exploring the combination of pAMP-based prophylactic antigen immunization (KNX-001/KNX-002) with the antiviral therapeutic component (KNX-003) into a single preventive/therapeutic vaccine candidate.
Such a combination would offer both pre-exposure protection and post-exposure therapeutic benefit in a single administration — a format with no precedent for either hantavirus or RVFV. The concept leverages the patented pAMP platform's modularity: combining prophylactic and therapeutic concatemeric components requires no change in manufacturing platform or delivery format.
KNX-004 is under active scientific discussion. No formal development decision has been made.
KNX-004
Program profile
- Platform
- Patented pAMP concatemeric peptide
- Pathogens
- RVFV & Hantavirus
- Indication
- Preventive / therapeutic combination vaccine
- Modality
- Prophylactic + therapeutic
- Stage
- Concept — under discussion
- Rationale
- pAMP modularity enables antiviral therapeutic + prophylactic vaccine in single format
Platform Advantages
Why pAMP enables multi-program development
All four KNX programs share the same manufacturing platform, the same expression system, and the same regulatory pathway — compressing timelines and cost across the entire pipeline.
Stockpile-ready format
Thermostable, non-replicating constructs reduce cold-chain burden, supporting national stockpile and field-deployment scenarios across all programs.
No live virus required
Standard recombinant protein production avoids live-virus handling and specialized containment infrastructure, enabling scale-up without BSL-3/4 manufacturing facilities.
Vaccines and therapeutics
The patented pAMP platform is modular across modalities — the same platform that builds prophylactic vaccine antigens also polymerizes therapeutic inhibitor peptides, enabling both product types from one technology base.
Rapid pathogen expansion
New pathogen programs are initiated by designing epitope concatemers against the target — no new platform, no new delivery system, no new manufacturing process.
Cross-pathogen targets
KNX-003 targets a conserved viral virulence factor across both RVFV and hantavirus — a single therapeutic candidate addressing multiple high-priority pathogens simultaneously.
Program officers and partners welcome
Contact us for program details, preclinical plans, and collaboration opportunities across the KNX pipeline and the pAMP platform.